article thumbnail

Bridging science and technology: a biotech CEO’s perspective

Drug Target Review

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge. Raminderpal earned his PhD in semiconductor modelling in 1997. For more: [link] ; [link] ; [link] ; Neil Wilkie, CEO, Mironid.

Science 52
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

from 2003 to 2006, covering the biotechnology and life-science tools sectors. Normality sensing licenses local T cells for innate-like tissue surveillance. J Exp Med 198(5):747-755 (2003). Kabelitz D, Serrano R, Kouakanou L, et al. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell Mol Immunol 17:925-939 (2020).

Therapies 105
article thumbnail

Decades Later, Congress Continues Debating the Preserve Access to Affordable Generics (and Biosimilars) Act; But will the Recent Jarkesy SCOTUS Decision Finally Put an End to the Insanity?

FDA Law Blog: Biosimilars

But like cockroaches, some pieces of legislation are resilient and never seem to die.

article thumbnail

Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

The Pharma Data

Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. with Xolair since its initial approval in 2003. today announced that the U.S. indications.

article thumbnail

BioArctic receives European patent for new antibodies targeting Alzheimer’s disease

The Pharma Data

The company was founded in 2003 based on innovative research from Uppsala University , Sweden. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.

Disease 40
article thumbnail

PREA and Fixed-Dose Combinations: When Things Get Complicated

The Premier Consulting Blog

The Pediatric Research Equity Act (PREA) was signed into law in 2003 to increase pediatric use information in product labeling and close knowledge gaps regarding the safety, efficacy, and appropriate dosing of drugs to treat children.

article thumbnail

U.S. FDA ACCEPTS FOR PRIORITY REVIEW

The Pharma Data

Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. 2003 Dec 12;22(2):217-23. NEW YORK–(BUSINESS WIRE)– Pfizer Inc.

FDA 52